Market Overview

Presbia Announces Board and Management Changes and Financing Proposal to Operate Through to the End of 2018

Share:

Presbia PLC (NASDAQ:LENS, or the "Company")), an ophthalmic device
company and leader in near-vision restoration, announces that it has
re-ordered its operational priorities to focus its resources on FDA
approval as well as ongoing clinical and commercial efforts in Germany
and South Korea. These actions reduce the Company's cash burn rate by
eliminating pre-FDA approval marketing, manufacturing and engineering
expenses related to the post-FDA approval U.S. commercial launch of the
Presbia Flexivue Microlens™. Presbia's efforts are focused on the
valuable intellectual property developed by the Company since 2008.

In parallel, Presbia has received an investment proposal from Orchard
Capital Corporation, which is affiliated with Presbia's majority
shareholder, to invest up to $5 million in the Company's preferred
shares. The proposed investment, together with existing cash-on-hand and
a reduced burn rate, is expected to fund Presbia's operations for the
entirety of 2018 and through the anticipated FDA approval of the
Flexivue Microlens™. Presbia continues to explore other financing
options and plans to finalize the capital raise by mid-February 2018.

Also, the board of directors accepted the resignation of Randy Thurman,
Executive Chairman, and Todd Cooper, board member, President and CEO,
effective on December 11, 2017. The board of directors elected Mark Yung
as Executive Chairman of the board and CEO of Presbia. Mark Yung has
previous experience as chairman, CEO and senior management of various
technology and manufacturing companies, where he successfully led
strategy setting and execution.

"The board thanks Randy Thurman and Todd Cooper for their dedicated
leadership at Presbia," said Mr. Yung. "This is an exciting time to join
Presbia as it advances through to its final PMA module submission, and
to assist in making the Flexivue Microlens™ available as an FDA-approved
optical lens implant to over 1.8 billion presbyopes globally."

This press release does not constitute an offer to sell or the
solicitation of an offer to buy these securities, nor will there be any
sale of these securities in any state or other jurisdiction in which
such offer, solicitation or sale would be unlawful prior to registration
or qualification under the securities laws of any such state or
jurisdiction.

Forward-Looking Statements

This release contains "forward-looking statements" made pursuant to the
safe harbor provisions of the Private Securities Litigation Reform Act
of 1995. Information provided and statements contained in this press
release that are not purely historical are forward-looking statements,
including statements related to the timing, amount, pricing and other
terms and completion of the proposed investment, the expected costs
associated with termination benefits and the financial impact of the
reduction in force. Such forward-looking statements only speak as of the
date of this press release and Presbia assumes no obligation to update
the information included in this press release. Statements made in this
press release that are forward-looking in nature may involve risks and
uncertainties, including, but not limited to, the factors listed under
"Risk Factors" in our annual report on Form 10-K for the year ended
December 31, 2016, quarterly reports on Form 10-Q, and other reports
that Presbia files with the SEC. Accordingly, readers are cautioned that
any such forward-looking statements are not guarantees and are subject
to certain risks, uncertainties and assumptions that are difficult to
predict. Although Presbia believes that the expectations reflected in
such forward-looking statements are reasonable as of the date made,
expectations may prove to have been materially different from the
results expressed or implied by such forward-looking statements. Unless
otherwise required by law, Presbia also disclaims any obligation to
update its view of any such risks or uncertainties or to announce
publicly the result of any revisions to the forward-looking statements
made in this press release.

About Presbia

Presbia PLC (NASDAQ:LENS) is an ophthalmic device company that has
developed and is currently marketing the
presbyopia-correcting Presbia Flexivue Microlens™, a miniature lens that
is implanted in a corneal pocket created by a femtosecond laser. The
Presbia Flexivue Microlens™ has received a CE mark for the European
Economic Area, allowing the lens to be marketed in over 30 countries
across Europe. A staged pivotal U.S. clinical trial for the Presbia
Flexivue Microlens™ commenced in 2014.

View Comments and Join the Discussion!
 
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com